The morbidity and mortality rate of Guillain-Barre syndrome is about 5%, but the disease is self-limiting, and most of them have a good prognosis after standardized treatment. Guillain-Barre syndrome is an acute inflammatory peripheral neuropathy mediated by autoimmunity. The exact cause of the disease is unknown and may be related to autoimmunity and infection. The disease has a rapid onset and can lead to motor and sensory deficits. In severe cases, it may be complicated by respiratory failure, hypotension, and severe cardiac arrhythmia, with a mortality rate of about 5%. However, the disease is self-limiting and most of them can return to normal after a period of time. In the acute stage, immunoglobulin injection and plasma exchange can reduce the abnormal immune response of the body. The disease is lethal to a certain extent, but with standardized treatment as prescribed by the doctor, a good prognosis can be achieved.